{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:49:40Z","timestamp":1791560980777,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41409-026-02976-0","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:32:04Z","timestamp":1784345524000},"page":"1353-1360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early inflammatory complications after haploidentical hematopoietic stem cell transplantation with post transplant cyclophosphamide for acute leukemia: a pediatric multicenter experience"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0005-4127","authenticated-orcid":false,"given":"Filomena","family":"Pierri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-0446","authenticated-orcid":false,"given":"Francesco","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9257-900X","authenticated-orcid":false,"given":"Franca","family":"Fagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7788-6407","authenticated-orcid":false,"given":"Stefano","family":"Giardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pestarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-5876","authenticated-orcid":false,"given":"Davide","family":"Leardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Masetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5715-501X","authenticated-orcid":false,"given":"Maura","family":"Faraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"2976_CR1","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.3390\/ijms25126380","volume":"25","author":"A Marszo\u0142ek","year":"2024","unstructured":"Marszo\u0142ek A, Le\u015bniak M, Sekunda A, Siwek A, Skiba Z, Lejman M, et al. Haploidentical HSCT in the Treatment of Pediatric Hematological Disorders. Int J Mol Sci. 2024;25:6380.","journal-title":"Int J Mol Sci"},{"key":"2976_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/cancers16030600","volume":"16","author":"T Nishikawa","year":"2024","unstructured":"Nishikawa T. Human Leukocyte Antigen-Haploidentical Haematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide for Paediatric Haematological Malignancies. Cancers. 2024;16:600.","journal-title":"Cancers"},{"key":"2976_CR3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/bjh.70004","volume":"207","author":"R Masetti","year":"2025","unstructured":"Masetti R, Leardini D, Gottardi F, Baccelli F, Ottaviano GAM, Vendemini F, et al. Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCR\u03b1\u03b2\/CD19 depletion or post-transplant cyclophosphamide. Br J Haematol. 2025;207:929\u201337.","journal-title":"Br J Haematol"},{"key":"2976_CR4","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry. CGl. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129:2357\u201373.","journal-title":"J Clin Invest"},{"key":"2976_CR5","first-page":"111.e1","volume":"28","author":"S Otoukesh","year":"2022","unstructured":"Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, et al. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transpl Cell Ther. 2022;28:111.e1\u2013111.e8.","journal-title":"Transpl Cell Ther"},{"key":"2976_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/hon.2772","volume":"38","author":"L Sol\u00e1n","year":"2020","unstructured":"Sol\u00e1n L, Landete E, Bail\u00e9n R, Dorado N, Oarbeascoa G, Anguita J, et al. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide. Hematol Oncol. 2020;38:597\u2013603.","journal-title":"Hematol Oncol"},{"key":"2976_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","volume":"22","author":"R Abboud","year":"2016","unstructured":"Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, et al. Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. Biol Blood Marrow Transpl. 2016;22:1851\u201360.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s10875-019-00600-z","volume":"39","author":"R Uppuluri","year":"2019","unstructured":"Uppuluri R, Sivasankaran M, Patel S, Swaminathan VV, Ramanan KM, Ravichandran N, et al. Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immune Deficiency Disorders in Children: Challenges and Outcome from a Tertiary Care Center in South India. J Clin Immunol. 2019;39:182\u20137.","journal-title":"J Clin Immunol"},{"key":"2976_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/petr.70220","volume":"29","author":"VC Patil","year":"2025","unstructured":"Patil VC, Dodda SR, Boyella PK, Tewani RK, Ladda PJ, Somayajula AA, et al. Impact of Early Cyclosporine on Cytokine Release Syndrome and Outcomes in Pediatric Haploidentical Hematopoietic Stem Cell Transplantation. Pediatr Transpl. 2025;29:e70220. https:\/\/doi.org\/10.1111\/petr.70220.","journal-title":"Pediatr Transpl"},{"key":"2976_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.841117","volume":"12","author":"SHC Baumeister","year":"2022","unstructured":"Baumeister SHC, Mohan GS, Elhaddad A, Lehmann L. Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. Front Oncol. 2022;12:841117.","journal-title":"Front Oncol"},{"key":"2976_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","volume":"218","author":"A Iqubal","year":"2019","unstructured":"Iqubal A, Iqubal MK, Sharma S, Ansari MA, Najmi AK, Ali SM, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sci. 2019;218:112\u201331.","journal-title":"Life Sci"},{"key":"2976_CR12","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1182\/bloodadvances.2019000143","volume":"3","author":"S Pagliuca","year":"2019","unstructured":"Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, et al. Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv. 2019;3:2424\u201335.","journal-title":"Blood Adv"},{"key":"2976_CR13","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2011.65","volume":"46","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transpl. 2011;46:1495\u2013502.","journal-title":"Bone Marrow Transpl"},{"key":"2976_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.trim.2017.06.004","volume":"43-44","author":"S Nomura","year":"2017","unstructured":"Nomura S, Ishii K, Fujita S, Nakaya A, Satake A, Ito T. Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2017;43-44:27\u201332.","journal-title":"Transpl Immunol"},{"key":"2976_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.mehy.2008.12.028","volume":"72","author":"H Zhou","year":"2009","unstructured":"Zhou H, Li Q, Zou P, You Y. Endothelial cells: a novel key player in immunoregulation in acute graft-versus-host disease?. Med Hypotheses. 2009;72:567\u20139.","journal-title":"Med Hypotheses"},{"key":"2976_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01894-7","volume":"40","author":"S Maqbool","year":"2022","unstructured":"Maqbool S, Nadeem M, Shahroz A, Naimat K, Khan I, Tahir H, et al. Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management. Med Oncol. 2022;40:36.","journal-title":"Med Oncol"},{"key":"2976_CR17","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.3346\/jkms.2019.34.e29","volume":"34","author":"M Park","year":"2019","unstructured":"Park M, Lee YH, Kang HR. Engraftment syndrome in pediatric allogeneic hematopoietic stem cell transplantation: a single-center experience. J Korean Med Sci. 2019;34:e29.","journal-title":"J Korean Med Sci"},{"key":"2976_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41409-023-02123-z","volume":"59","author":"DJ Ikeda","year":"2024","unstructured":"Ikeda DJ, DeFilipp Z, Collier K, Chen YB, Dey BR, El-Jawahri A, et al. Low incidence of engraftment syndrome following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transpl. 2024;59:131\u20133.","journal-title":"Bone Marrow Transpl"},{"key":"2976_CR19","doi-asserted-by":"crossref","unstructured":"Valc\u00e1rcel D, S\u00e1nchez-Ortega I, Sureda A. Graft failure. In: Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E, editors. EBMT Handbook. Ch. 41. Cham: Springer; 2024, p. 365-372.","DOI":"10.1007\/978-3-031-44080-9_41"},{"key":"2976_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:4\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e1.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR23","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1182\/bloodadvances.2025016233","volume":"9","author":"Y Akahoshi","year":"2025","unstructured":"Akahoshi Y, Inamoto Y, Spyrou N, Nakasone H, Diniz MA, Asada N, et al. Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC. Blood Adv. 2025;9:4640\u201353.","journal-title":"Blood Adv"},{"key":"2976_CR24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transpl. 2015;21:984\u201399.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR25","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.bbmt.2010.05.019","volume":"16","author":"JE Levine","year":"2010","unstructured":"Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bola\u00f1os-Meade J, et al. Blood and Marrow Transplant Clinical Trials Network. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transpl. 2010;16:1693\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.bbmt.2009.03.012","volume":"15","author":"PJ Martin","year":"2009","unstructured":"Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transpl. 2009;15:777\u201384.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","volume":"27","author":"TR Spitzer","year":"2001","unstructured":"Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transpl. 2001;27:893\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2976_CR29","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.bbmt.2018.04.010","volume":"24","author":"RV Raj","year":"2018","unstructured":"Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, et al. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transpl. 2018;24:1664\u201370.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR30","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1038\/s41409-019-0522-4","volume":"54","author":"MM Solh","year":"2019","unstructured":"Solh MM, Dickhaus E, Solomon SR, Morris LE, Zhang X, Holland HK, et al. Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes. Bone Marrow Transpl. 2019;54:1756\u201363.","journal-title":"Bone Marrow Transpl"},{"key":"2976_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ajh.27594","volume":"100","author":"JE Levine","year":"2025","unstructured":"Levine JE. Prediction and Prognostication of Acute Graft-Versus-Host Disease by MAGIC Biomarkers. Am J Hematol. 2025;100:5\u201313.","journal-title":"Am J Hematol"},{"key":"2976_CR32","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1182\/blood.2024025106","volume":"144","author":"Y Akahoshi","year":"2024","unstructured":"Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, et al. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD. Blood. 2024;144:1010\u201321.","journal-title":"Blood"},{"key":"2976_CR33","first-page":"603.e1","volume":"30","author":"M Qayed","year":"2024","unstructured":"Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, Ayuk FA, et al. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD. Transpl Cell Ther. 2024;30:603.e1\u2013603.e11.","journal-title":"Transpl Cell Ther"},{"key":"2976_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1200\/JCO.2004.06.102","volume":"22","author":"O Ringd\u00e9n","year":"2004","unstructured":"Ringd\u00e9n O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the acute leukemia working party of the european group for blood and marrow transplantation. J Clin Oncol. 2004;22:416\u201323.","journal-title":"J Clin Oncol"},{"key":"2976_CR35","first-page":"544","volume":"11","author":"AK Gupta","year":"2021","unstructured":"Gupta AK, Meena JP, Haldar P, Tanwar P, Seth R. Impact of G-CSF administration post-allogeneic hematopoietic stem-cell transplantation on outcomes: a systematic review and meta-analysis. Am J Blood Res. 2021;11:544\u201363.","journal-title":"Am J Blood Res"},{"key":"2976_CR36","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41409-024-02388-y","volume":"59","author":"S Escribano-Serrat","year":"2024","unstructured":"Escribano-Serrat S, Pedraza A, Su\u00e1rez-Lled\u00f3 M, Charry P, De Moner B, Martinez-Sanchez J, et al. Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation. Bone Marrow Transpl. 2024;59:1466\u201376.","journal-title":"Bone Marrow Transpl"},{"key":"2976_CR37","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","volume":"39","author":"L Luznik","year":"2012","unstructured":"Luznik L, O\u2019Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683\u201393.","journal-title":"Semin Oncol"},{"key":"2976_CR38","first-page":"438.e1","volume":"30","author":"J Tang","year":"2024","unstructured":"Tang J, Jensen RR, Bryan B, Hoda D, Hunter BD. Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplantation. Transpl Cell Ther. 2024;30:438.e1\u2013438.e11.","journal-title":"Transpl Cell Ther"},{"key":"2976_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000521211","volume":"145","author":"V Uygun","year":"2022","unstructured":"Uygun V, Karasu G, Yal\u00e7\u0131n K, \u00d6zt\u00fcrkmen S, Dalo\u011flu H, \u00c7elen SS, et al. Timing of Initiation of Calcineurin Inhibitors in Pediatric Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Effects on Survival, Relapse, and Cytokine Release Syndrome. Acta Haematol. 2022;145:362\u201370.","journal-title":"Acta Haematol"},{"key":"2976_CR40","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00277-021-04439-6","volume":"100","author":"N Kurita","year":"2021","unstructured":"Kurita N, Sakamoto T, Kato T, Kusakabe M, Yokoyama Y, Nishikii H, et al. Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide. Ann Hematol. 2021;100:1295\u2013301.","journal-title":"Ann Hematol"},{"key":"2976_CR41","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","volume":"26","author":"A Ruggeri","year":"2020","unstructured":"Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JL, et al. Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2020;26:1915\u201322.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2976_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231152644","volume":"14","author":"A Ngwube","year":"2023","unstructured":"Ngwube A, Rangarajan H, Shah N. Role of abatacept in the prevention of graft-versus-host disease: current perspectives. Ther Adv Hematol. 2023;14:20406207231152644. Feb 9.","journal-title":"Ther Adv Hematol"},{"key":"2976_CR43","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/JCO.20.01086","volume":"39","author":"B Watkins","year":"2021","unstructured":"Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021;39:1865\u201377.","journal-title":"J Clin Oncol"},{"key":"2976_CR44","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1182\/blood.2023020035","volume":"142","author":"T Takahashi","year":"2023","unstructured":"Takahashi T, Al-Kofahi M, Jaber M, Bratrude B, Betz K, Suessmuth Y, et al. Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events. Blood. 2023;142:700\u201310.","journal-title":"Blood"},{"key":"2976_CR45","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/bloodadvances.2023010545","volume":"7","author":"AS Al-Homsi","year":"2023","unstructured":"Al-Homsi AS, Cirrone F, Wo S, Cole K, Suarez-Londono JA, Gardner SL, et al. PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation. Blood Adv. 2023;7:3604\u201311.","journal-title":"Blood Adv"},{"key":"2976_CR46","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood.2024026497","volume":"145","author":"R Abboud","year":"2025","unstructured":"Abboud R, Schroeder MA, Rettig MP, Jayasinghe RG, Gao F, Eisele J, et al. Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation. Blood. 2025;145:1382\u201394.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02976-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02976-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02976-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:01:59Z","timestamp":1791558119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02976-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2976"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02976-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"We confirm that all methods were performed in accordance with the relevant guidelines and regulations. This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the ethics committee of IRCCS Istituto G. Gaslini, Genova, Italy (EudraCT, EU-CT number 2012-000703-32). Informed consent was obtained from all participants or their legal guardians prior to data collection.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}